A Dutch RCT shows structured urate titration beats out symptom-driven care.
Treating gout to a serum urate target delivers superior long-term disease control compared with symptom-driven care, according to the first pragmatic, head-to-head randomised trial to test the competing strategies in routine practice.
The GO TEST Overture study, a multicentre, open-label superiority trial conducted across eight rheumatology centres in the Netherlands, randomised 308 adults with gout and hyperuricaemia not receiving urate-lowering therapy to either a structured treat-to-target approach or symptom-driven management guided by patient and clinician preference.
Participants were followed for 24 months in a design intended to mirror real-world outpatient care rather than tightly controlled efficacy settings.
Results have been published in The Lancet Rheumatology.
“A treat-to-target strategy was associated with improved long-term disease control compared with symptom-driven care, without evidence of increased adverse events,” the researchers wrote.
“These findings provide support for the use of systematic serum urate-guided urate-lowering therapy titration in the routine management of gout.”
By the final six months of follow-up, remission – defined using adapted preliminary gout criteria requiring no flares, no tophi, low pain (NRS <2) and high patient global assessment (>8) – was achieved in 39.4% of patients in the treat-to-target arm compared with 24.0% in the symptom-driven group.
This represented an absolute difference of 15.4 percentage points (95% CI 6.4–24.4). Sensitivity analyses using full and simplified remission definitions yielded consistent results, with even larger separation when objective components such as serum urate were emphasised.
The interventional contrast was strong. In the treat-to-target arm, urate-lowering therapy was initiated with allopurinol and titrated every four to eight weeks up to a maximum of 900mg daily, with escalation to febuxostat or benzbromarone where needed, aiming for serum urate <0.36 mmol/L (or <0.30 mmol/L in tophaceous disease). Regular monitoring and prophylactic anti-inflammatory therapy were incorporated early.
By comparison, the symptom-driven strategy allowed discretionary initiation and dosing of urate-lowering therapy without biochemical targets or routine urate monitoring, with flares managed reactively.
These divergent strategies translated into large differences in biochemical and clinical outcomes.
During months 18–24, 72.8% of patients in the treat-to-target group achieved serum urate <0.36 mmol/L versus 39.5% in the symptom-driven group, a 33.3 percentage point gap.
Achievement of more stringent targets (<0.30 mmol/L) showed similarly wide separation. Flare control also favoured treat-to-target, with 64.2% flare-free compared with 48.3% under symptom-driven care, and a significantly lower annualised flare rate in the second year (incidence rate ratio 0.62).
Despite these gains, differences in patient-reported pain, global assessment and physical function were modest, reflecting rapid early improvement in both arms and a relatively low symptom burden thereafter.
Tophi outcomes were also similar, likely due to low baseline prevalence. The researchers noted that current patient-reported measures may lack sensitivity to discriminate between well-controlled states, with simplified remission definitions based on objective domains offering clearer separation.
Treatment exposure underscored the mechanistic advantage of the strategy. All patients in the treat-to-target group received urate-lowering therapy, compared with 78% in the symptom-driven arm, and mean allopurinol doses were substantially higher at 24 months (331.7mg vs 196.6 mg). Use of second-line agents was also more frequent, consistent with protocolised escalation.
Safety outcomes should reassure clinicians concerned about intensification, the researchers noted.
Adverse events were numerically lower in the treat-to-target group (42% vs 53%), with fewer non-serious events and no signal for increased serious adverse events, treatment-related deaths or drug-related complications.
Related
The trial directly addressed a long-standing divide in gout guidance, the researchers said.
“Before the GO TEST Overture trial, major guidelines differed in their recommendations for gout management: EULAR and ACR support lowering serum urate to a target (treat to target), whereas the ACP recommends symptom-driven management, citing insufficient evidence that targeting serum urate improves patient-centred outcomes,” they wrote.
“This trial directly addresses that gap, showing that a treat-to-target strategy results in superior disease control without additional safety concerns.
“These findings clarify the benefits of a treat-to-target strategy and might inform future clinical guidelines and health policy.”
Even within a structured protocol, only around 63% of patients achieved the target serum urate threshold, highlighting persistent barriers including adherence, patient perceptions of biochemical goals, and the realities of shared decision-making.
The comparator arm, where dose escalation was limited and monitoring infrequent, likely reflected common practice outside specialist-led treat-to-target frameworks.
Several factors probably contributed to this outcome, the researchers concluded.
“First, urate-lowering therapy was implemented using shared decision making, reflecting standard Dutch clinical practice, which might have reduced adherence to aggressive titration schedules, because many patients do not perceive serum urate as a personally meaningful goal,” they wrote.
“Second, adherence challenges typical of long-term gout management probably restricted a sustained biochemical response.
“Finally, the symptom-driven management group, in which allopurinol doses were seldom escalated beyond 100mg daily, provides a realistic real-world comparator rather than a fully optimised regimen.
“Together, these elements illustrate the balance between pragmatic trial design and attainable treatment targets in routine care.
“Future studies are needed to confirm the long-term benefits of treat-to-target approaches and to explore implementation strategies that support adherence and equitable access to care in routine clinical settings.”
